STOCK TITAN
  1. Home
  2. News
  3. ATHE

Alterity Therapeutics Ltd - ATHE STOCK NEWS

Welcome to our dedicated news page for Alterity Therapeutics (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alterity Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alterity Therapeutics's position in the market.

News
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Rhea-AI Summary
Alterity Therapeutics presented data at the American Academy of Neurology 2024 Annual Meeting showcasing the positive effects of ATH434 in Parkinson's Disease and Multiple System Atrophy. The company's work in Parkinson's disease and MSA, including baseline data from the ATH434-201 Phase 2 trial, was highlighted. The data demonstrated improvements in motor skills and general functioning in a primate model of Parkinson's disease, validating the approach used in ongoing clinical trials. The baseline characteristics from the Phase 2 trial showed increased iron levels in areas of pathology and elevated plasma Neurofilament Light Chain levels correlating with disease severity. The results suggest ATH434's potential as a disease-modifying therapy for neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
-
News
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE) to present new data on ATH434 at World Orphan Drug Congress and American Academy of Neurology meetings. The data focuses on unique iron-targeting drug for neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.66%
Tags
conferences
-
News
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Rhea-AI Summary
Alterity Therapeutics receives A$3.9 million cash refund for R&D activities, to advance Phase 2 clinical trials in MSA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
News
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
Rhea-AI Summary
Alterity Therapeutics to Present Positive Efficacy Data for ATH434 in Parkinson's Disease Model at AAN 2024 Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences
-
News
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
Rhea-AI Summary
Alterity Therapeutics announces that the ATH434-201 Phase 2 clinical trial for treating multiple system atrophy (MSA) is on track to complete in November 2024, with top-line data expected in January 2025. An independent Data Monitoring Committee has recommended the study to continue as planned, with no concerns expressed during the review of unblinded clinical data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
clinical trial
-
News
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
Rhea-AI Summary
Alterity Therapeutics CEO to participate in ShareCafe Hidden Gems webinar on February 1 and 2, 2024, for Australian and US participants, offering an archived replay. The event aims to provide further details on the company's disease modifying treatments for neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
conferences
News
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Rhea-AI Summary
Alterity Therapeutics (ATHE) has issued a letter to shareholders outlining key milestones for 2024, including the completion of the ATH434-201 study in November 2024 and the expected preliminary data from the ATH434-202 study in 1H 2024. The company remains committed to developing disease-modifying treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA), and is focused on their lead clinical development candidate, ATH434. The drug has been granted Orphan Drug Designation (ODD) for the treatment of MSA by the U.S. FDA and the European Commission, and the primary Phase 2 clinical trial (ATH434-201) is treating participants for 12 months, with topline results expected in January 2025. Additionally, a second Phase 2 clinical trial (ATH434-202) is ongoing, with preliminary six-month data expected in the first half of this year. The company is also conducting the bioMUSE Natural History study, which continues to generate invaluable data related to the understanding of MSA and its early presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
News
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the appointment of Phillip Hains as the new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has almost 30 years of experience in corporate secretarial, accounting, and general management. This follows the resignation of Kathryn Andrews, who has been CFO since 2014. The company expressed deep appreciation for Kathryn's contributions and looks forward to expanding the relationship with Phillip in 2024, a pivotal year for Alterity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
management
-
News
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will be hosting an investor webcast to discuss the ATH434 efficacy data in primates and recent clinical progress. The webcast will be held on December 6, 2023, for Australia participants and December 5, 2023, for the United States participants. Registration is required, and investors can submit questions in advance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.86%
Tags
conferences
News
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced promising new data on the effect of ATH434 in a Parkinson’s disease primate model, demonstrating improved motor performance and general function. The study compared daily oral doses of ATH434 versus a placebo, showing stable or improving Parkinson Behavior Rating Scale scores in ATH434-treated monkeys, indicating reduced motor impairment and improved general functions. A webcast will be held to discuss the new data and recent clinical progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
153.01%
Tags
none
Stock ATHE logo
Alterity Therapeutics Ltd

Nasdaq:ATHE

ATHE Rankings

#5100 Ranked by Market Cap
#4167 Ranked by Stock Gains
N/A Ranked by Dividends

ATHE Stock Data

17.90M
2.54B
1%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About ATHE

alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.